Interested in Connecting? Please contact: Agnieszka Janeczek CEO firstname.lastname@example.org
Message the company or request a 1:1 meeting here.
Renovos is pioneering the use of synthetic nanoclay gels to deliver, retain and safely release biologics for regenerative medicine and orthopaedic applications. Renovos’ proprietary formulations, Renovite, are easy to handle, form a biodegradable gel after injection, and can deliver 100X lower doses than traditional formulations of biologics with the same efficacy, as the Renovite platform retains active agents and releases them only to target cells interacting with the nanoclay. Renovos’ mission is to unlock the full potential of regenerative medicine with our innovative Renovite technology platform, and help clinicians deliver safe and more efficacious treatments for tissue repair, addressing a $5.7bn orthobiologics market. Renovos has a granted patent and a strong scientific and commercial team. The company is now raising £10m to complete pre-clinical development and enable clinical trials.